Want to see AU:FRE full AI Analyst Report?
Top Page
Firebrick Pharma Limited
(Sydney:FRE)
Select Model
Select Model
Rating:45Neutral
Price Target:
AU$0.03
▼(-38.00% Downside)
Action:Reiterated
Date:09/06/26
The score is held down primarily by very weak financial performance—sharp revenue contraction, persistent losses, and continued cash burn despite being debt-free. Technicals are mixed (short-term stabilization but weak longer-term trend), while valuation remains challenged due to negative earnings and no dividend support.
Positive Factors
Debt-free balance sheet
A debt-free balance sheet reduces mandatory interest and principal obligations, giving Firebrick greater flexibility while it develops and commercializes products. Lower leverage also limits refinancing exposure and provides a more stable foundation than a similarly loss-making business carrying significant debt.
Negative Factors
Severe revenue contraction
The sharp FY2026 revenue decline demonstrates substantial volatility in the commercial base and weakens confidence in near-term scale. Persistent contraction can reduce operating leverage, limit reinvestment capacity, and make future product commercialization more dependent on successful launches.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
A debt-free balance sheet reduces mandatory interest and principal obligations, giving Firebrick greater flexibility while it develops and commercializes products. Lower leverage also limits refinancing exposure and provides a more stable foundation than a similarly loss-making business carrying significant debt.
Read all positive factors
Firebrick Pharma Limited (FRE) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$9.19M
Dividend YieldN/A
Average Volume (3M)180.98K
Price to Earnings (P/E)―
Beta (1Y)-0.38
Revenue Growth-63.86%
EPS Growth4.00%
CountryAU
Employees6
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - General
Share Statistics
EPS (TTM)-0.01
Shares Outstanding287,198,970
10 Day Avg. Volume51,523
30 Day Avg. Volume180,984
Financial Highlights & Ratios
PEG Ratio0.75
Price to Book (P/B)5.44
Price to Sales (P/S)86.36
P/FCF Ratio-3.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Firebrick Pharma Limited Business Overview & Revenue Model
Company Description
Firebrick Pharma Limited, an enterprise established in 2012 and headquartered in Melbourne, Australia, is dedicated to the research, development, and market launch of Nasodine, a nasal spray treatment for the common cold, exclusively for the Austr...
How the Company Makes Money
Firebrick Pharma’s primary way of making money is through commercializing its prescription pharmaceutical products in markets where it obtains regulatory approval. Revenue is generated mainly from sales of its own branded medicines to, or through,...
Firebrick Pharma Limited Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
53
Neutral
Cash Flow
18
Very Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 106.03K | 293.42K | 14.52K | 830.00 | 4.12K |
| Gross Profit | -1.04M | 104.82K | -22.78K | 830.00 | 4.12K |
| EBITDA | -3.10M | -2.86M | -1.17M | -6.81M | -4.86M |
| Net Income | -3.06M | -2.63M | -1.18M | -6.80M | -3.80M |
Balance Sheet | |||||
| Total Assets | 2.17M | 1.83M | 2.41M | 2.98M | 8.73M |
| Cash, Cash Equivalents and Short-Term Investments | 1.32M | 983.35K | 824.78K | 2.35M | 7.14M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 483.03K | 271.28K | 291.07K | 506.44K | 450.10K |
| Stockholders Equity | 1.68M | 1.56M | 2.12M | 2.48M | 8.28M |
Cash Flow | |||||
| Free Cash Flow | -2.60M | -1.86M | -2.35M | -5.78M | -4.23M |
| Operating Cash Flow | -2.60M | -1.78M | -2.34M | -5.78M | -4.20M |
| Investing Cash Flow | 0.00 | -82.98K | -134.00 | -1.62K | -32.54K |
| Financing Cash Flow | 2.94M | 2.02M | 815.21K | 996.65K | 10.23M |
Firebrick Pharma Limited Technical Analysis
Negative
0.05
Price Trends
0.03
Negative
0.04
Negative
0.05
Negative
Market Momentum
<0.01
Negative
48.71
Neutral
72.22
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:FRE, the sentiment is Negative. The current price of 0.05 is above the 20-day moving average (MA) of 0.03, above the 50-day MA of 0.03, and above the 200-day MA of 0.05, indicating a bearish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 48.71 is Neutral, neither overbought nor oversold. The STOCH value of 72.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:FRE.
Firebrick Pharma Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | AU$254.68M | 10.03 | 6.58% | 12.09% | -5.98% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$18.96M | -7.19 | -13.81% | 6.27% | 5.93% | 66.32% | |
47 Neutral | AU$57.47M | -0.65 | -118.74% | ― | 499.47% | 31.20% | |
45 Neutral | AU$9.19M | -2.67 | -169.20% | ― | -63.86% | 4.00% | |
44 Neutral | AU$9.64M | -1.30 | -6182.61% | ― | ― | 62.90% | |
43 Neutral | AU$12.91M | -3.10 | -31.88% | ― | 5.85% | 42.92% |
* Healthcare Sector Average
AU:FRE
Firebrick Pharma Limited
0.03
-0.05
-58.44%
AU:MYX
Mayne Pharma Group
3.11
-1.39
-30.89%
AU:IMC
Immuron Limited
0.04
-0.03
-42.86%
AU:1AD
AdAlta Ltd.
―
―
―
AU:IDT
IDT Australia Limited
0.05
-0.02
-29.23%
AU:BOT
Botanix Pharmaceuticals Limited
0.02
-0.12
-85.00%
Firebrick Pharma Limited Corporate Events
Firebrick Pharma lodges ASX governance disclosures for 2026
Aug 31, 2026
Firebrick Pharma has lodged its Appendix 4G with the ASX for the financial year ended 30 June 2026, confirming that its corporate governance statement is current as at 31 August 2026 and available on its investor website. The filing indicates the ...
Firebrick Pharma Revenue Slides as Loss Widens and Asset Backing Erodes
Aug 31, 2026
Firebrick Pharma Limited reported a sharp decline in revenue from ordinary activities to $106,000 for the year ended 30 June 2026, down from $293,000 a year earlier, highlighting weaker commercial performance. The company operates in the pharmaceu...
Firebrick Pharma Issues Shares to Consultant in Lieu of Fees
Aug 10, 2026
Firebrick Pharma Limited has issued 2,000,000 ordinary fully paid shares to a consultant in lieu of cash service fees, at an issue price of $0.026 per share, and has notified the market under section 708A of the Corporations Act. The company confi...
Firebrick Pharma Seeks ASX Quotation for 2 Million New Shares
Aug 10, 2026
Firebrick Pharma Limited has lodged an application with the ASX for quotation of 2,000,000 ordinary fully paid shares under its FRE ticker. The new securities, issued on August 10, 2026, expand the company’s listed share base and reflect ong...
Firebrick Pharma Plans Placement of Up to 2 Million New Shares
Aug 9, 2026
Firebrick Pharma Limited has announced a proposed issue of up to 2,000,000 ordinary fully paid shares on the ASX under the code FRE. The securities are to be issued via a placement or other type of issue, with the proposed issue date set for 10 Au...
Firebrick Pharma Corrects Expiry Date on Employee Equity Securities
Jul 27, 2026
Firebrick Pharma Limited has issued an update to a previous ASX notification relating to unquoted equity securities under an employee offer. The company corrected the recorded expiry date of these employee-related securities, confirming that the o...
Firebrick Pharma Issues Confidential Investor Update With Strict Usage Limits
Jul 27, 2026
Firebrick Pharma Limited has issued a confidential investor update, emphasising that the material is strictly for a select audience of qualified investors and is not intended as public marketing or a general securities offer. The company underscor...
Firebrick Pharma Extends Patent Protection as Sales Grow 43% in FY26
Jul 27, 2026
Firebrick Pharma reported a steady operational quarter to 30 June 2026, highlighted by further strengthening of its intellectual property portfolio. The company secured acceptance of its pandemic-use povidone-iodine patent in Canada, already prote...
Firebrick Pharma Shifts Melbourne Headquarters Amid Nasodine Global Expansion
Jul 14, 2026
Firebrick Pharma Limited has updated its registered office and principal place of business to Level 14, 333 Collins Street in Melbourne, effective 20 July 2026, while retaining its existing telephone contact details. The administrative change unde...
Firebrick Pharma shareholders back all resolutions at General Meeting
Jun 22, 2026
Firebrick Pharma reported that all resolutions put to shareholders at its General Meeting on 22 June 2026 were passed by poll, including ratifications of prior share and option issues under various ASX listing rules. The strong support for these m...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.